🔗 Share this article

While the US proceeds with historic adjustments to its immunization guidelines, an unexpected name appears in a surprising turn: Høeg, a US-based sports physician and epidemiologist who initially gained attention by expressing skepticism about coronavirus vaccinations during the pandemic and has concentrated on potential fatalities following Covid immunization in her brief time at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Vaccine Program

Agency leaders had intended to unveil major revisions to the pediatric vaccine schedule earlier this month, aligning the US with Denmark’s immunization schedule, it is understood – a major change that would put the US out of alignment with a large portion of the international standard with no evidence for public health gain. The announcement has been postponed until the next year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to present at the gathering. She was just designated acting director of the FDA’s drug evaluation center, the fifth appointee to head the division this calendar year.

A Shift at the FDA

This interim role may indicate a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad solidify control at the agency – and it points to a renewed priority upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for halting certain pediatric immunization guidelines in the US so as to align more in line with the Danish model, a nation with nationalized medicine and a population approximately the size of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccines – usually the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Questions Over Background

Høeg has no apparent track record in drug development, oversight or leadership, which has been standard for previous heads of the CBER. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for running the CDER, said Jonathan Howard. “She’s never run a clinical trial. She is not versed in running a large organization. She lacks background in pharmaceutical oversight.”

Past heads of CBER would “understand laws and regulations and the science of pharmaceutical innovation”, noted a former acting FDA commissioner. “Frankly, she lacks the type of experience that former directors who led the center have had.”

CDER has an vast range of responsibilities at the FDA, Woodcock emphasized.

“Everybody just zeroes in on the novel medication approvals, but the generic drug division clears thousands of generic drugs. There’s a biosimilars division, OTC medication office and more, and each of these must be looked after,” Woodcock said. “The thing you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Additionally, a major leadership element to the job, which oversees in excess of 5,000 personnel. “It is a huge leadership role, if you perform it correctly,” she added.

Response and Controversial Initiatives

When asked about questions about Høeg’s qualifications and whether this assignment indicates increased cooperation among agency officials on vaccines, a spokesperson stated that the “concerns rely on flawed assumptions”.

“Her resume matches the functions of her job,” the representative stated, pointing to the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s new fast-track approval initiative, a contentious rapid therapy clearance system that allegedly worried her former heads. “By what process are these medications being selected for this voucher program? Who takes the decisions?” Dr. Howard asked. “There is a lot of secrecy going on at the agency right now.”

Broadly speaking, he stated, “the Food and Drug Administration seems to be moving towards laxer regulations of most medications, except for immunizations.”

Public History on Vaccines

Concerning vaccines, Høeg has a clearer, if troubling, history, critics said. She authored a study using unverified volunteer-provided data to assess the rate of heart inflammation following COVID-19 vaccination. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are riskier than they are.

Among her “wish list” for the new administration encompassed changing guidelines for recently developed shots and halting “unnecessary” vaccines, she said following the vote on a online show. At the agency, Dr. Høeg has according to sources floated the idea of excluding young men from obtaining Covid vaccines.

“She is an thorough true believer who begins with her conclusions and reverse-engineers to accommodate the evidence in a very disingenuous, untruthful way,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with other dissenters, {like|